Table 1.
The characteristic of the patients
| Patient characteristics | Values |
|---|---|
| (a) The characteristic of the patients and donors with allo‐HSCT | |
| Number of patients | 30 |
| Number of donors | 30 |
| Median patient age, year (range) | 28 (14–52) |
| Median donor age, year (range) | 35 (19–50) |
| Sex, no. (%) | |
| Male/female patients | 17/13 (56.7/43.3) |
| Male/female donors | 18/12 (60/40) |
| Disease diagnosis, no. (%) | |
| ALL | 8 (26.7) |
| AML | 15 (50) |
| MDS | 5 (16.7) |
| CML | 2 (6.7) |
| Disease status at transplantation, no. (%) | |
| CR | 29 (96.7) |
| PR | 1 (3.3) |
| Donor characteristics, no. (%) | |
| Matched sibling donor | 20 (66.7) |
| Mismatched sibling donor | 5 (16.7) |
| MUD | 5 (16.7) |
| Conditioning regimen | |
| Ara‐C/Bu/Flu/Me‐CCNU | 22 (73.3) |
| Ara‐C/Bu/Cy/Me‐CCNU | 8 (26.7) |
| GVHD prophylaxis | |
| CsA+MTX | 20 (66.7) |
| CsA+MTX+MMF | 10 (33.3) |
| Mobilization regimen | |
| G‐CSF | 30 (100) |
| Stem cell source | |
| Bone marrow + peripheral blood | 3 (10) |
| Peripheral blood | 27 (90) |
| (b) The characteristic of the patients developing aGVHD after allo‐HSCT | |
| Number | 17 |
| Median age, year (range) | 24 (14–52) |
| Sex, no.(%) | |
| Male | 10 (58.8) |
| Female | 7 (41.2) |
| Disease diagnosis, no. (%) | |
| ALL | 6 (35.3) |
| AML | 8 (47.1) |
| MDS | 2 (11.8) |
| CML | 1 (5.9) |
| Disease status at transplantation, no. (%) | |
| CR | 16 (94.1) |
| PR | 1 (5.9) |
| Donor characteristics, no. (%) | |
| Matched sibling donor | 11 (64.7) |
| Mismatched sibling donor | 3 (17.6) |
| MUD | 3 (17.6) |
| Conditioning regimen | |
| Ara‐C/Bu/Flu/Me‐CCNU | 10 (58.8) |
| Ara‐C/Bu/Cy/Me‐CCNU | 7 (41.2) |
| GVHD prophylaxis | |
| CsA+MTX | 11 (64.7) |
| CsA+MTX+MMF | 6 (35.3) |
| Stem cell source | |
| Bone marrow + peripheral blood | 3 (17.6) |
| Peripheral blood | 14 (82.4) |
MUD, matched unrelated donor; Ara‐C/Bu/Cy/Me‐CCNU, cytarabine (2–4 g/m2/day on days −10, −9), busulfan (3.2 mg/kg/day IV on days −8 to −6), cyclophosphamide (1.8 g/m2/day on days −5 and −4), Semustine (250 mg/m2/day on days −3); Ara‐C/Bu/Flu/Me‐CCNU, cytarabine (2–4 g/m2/day on days −10, −9), busulfan (3.2 mg/kg/day IV on days −7 to −5), fludarabine (30 mg/m2/day on days −12 to −8), Semustine (250 mg/m2/day on days −3); CsA, cyclosporin A (2.5 mg/kg/day every 12 h since day −10); MTX, methotrexate (15 mg/m2 on day 1 and 10 mg/m2 on days +3, +6, and +11); MMF, mycophenolate mofetil (1.0 g/day, from the beginning of conditioning therapy); G‐CSF, granulocyte colony‐stimulating factor. The donors were mobilized with G‐CSF (5 μg/kg/day) for 4–5 days.